N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity

Leukemia

Volumn 26, Issue 10, 2012, Pages 2260-2268

  Bruno, S ^a   Ghiotto, F ^a   Tenca, C ^a   Mazzarello, A N ^a   Bono, M ^a   Luzzi, P ^a   Casciaro, S ^a   Recchia, A ^b   Decensi, A ^c,d   Morabito, F ^b   Fais, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Azienda Ospedaliera di Cosenza   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

4HPR; Apoptosis; Chronic lymphocytic leukemia; Proliferation

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CD40 LIGAND; FENRETINIDE; FLUDARABINE; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL PROLIFERATION; DRUG SYNERGISM; FENRETINIDE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SULFONAMIDES; VIDARABINE;

EID: 84867401438     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.98     Document Type: Article

References (52)

1. Calissano C, Damle RN, Hayes G, Murphy EJ, Hellerstein MK, Moreno C et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009; 114: 4832-4842.
2. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755-764. (Pubitemid 40322252)
3. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563-574.
4. Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, Kater AP et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007; 109: 1660-1668. (Pubitemid 46242110)
5. Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466-1471. (Pubitemid 46594097)
6. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008; 111: 846-855.
7. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008; 112: 3807-3817.
8. Veronese L, Tournilhac O, Verrelle P, Davi F, Dighiero G, Chautard E et al. Low MCL-1 mRNA expression correlates with prolonged survival in B-cell chronic lymphocytic leukemia. Leukemia 2008; 22: 1291-1293. (Pubitemid 351833810)
9. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complementdependent cytotoxicity. Clin Cancer Res 2007; 13: 2144-2150. (Pubitemid 46649884)
10. Farber CM, Liebes LF, Kanganis DN, Silber R. Human B lymphocytes show greater susceptibility to H2O2 toxicity than T lymphocytes. J Immunol 1984; 132: 2543-2546. (Pubitemid 14136850)
11. Oltra AM, Carbonell F, Tormos C, Iradi A, Saez GT. Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med 2001; 30: 1286-1292. (Pubitemid 32463939)
12. Farber CM, Kanganis DN, Liebes LF, Silber R. Antioxidant enzymes in lymphocytes from normal subjects and patients with chronic lymphocytic leukaemia: increased glutathione peroxidase activity in CLL B lymphocytes. Br J Haematol 1989; 72: 32-35. (Pubitemid 19133764)
13. Children's Oncology Group (CCG 09709). Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH et al. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006; 24: 3423-3430. (Pubitemid 46638899)
14. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 2004; 22: 4282-4289. (Pubitemid 41185149)
15. Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S et al. Randomized double-blind 2 - 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 2009; 27: 3749-3756.
16. Decensi A, Bruno S, Costantini M, Torrisi R, Curotto A, Gatteschi B et al. Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. J Natl Cancer Inst 1994; 86: 138-140. (Pubitemid 24040153)
17. Colombo N, Formelli F, Cantu MG, Parma G, Gasco M, Argusti A et al. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1914-1919. (Pubitemid 44664268)
18. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 2008; 100: 580-595.
19. Darwiche N, Abou-Lteif G, Bazarbachi A. Reactive oxygen species mediate N-(4-hydroxyphenyl)retinamide-induced cell death in malignant T cells and are inhibited by the HTLV-I oncoprotein Tax. Leukemia 2007; 21: 261-269. (Pubitemid 46158118)
20. Morales MC, Perez-Yarza G, Rementeria NN, Boyano MD, Apraiz A, Gomez-Munoz A et al. 4-HPR-mediated leukemia cell cytotoxicity is triggered by ceramideinduced mitochondrial oxidative stress and is regulated downstream by Bcl-2. Free Radic Res 2007; 41: 591-601. (Pubitemid 46511124)
21. Boya P, Morales MC, Gonzalez-Polo RA, Andreau K, Gourdier I, Perfettini JL et al. The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family. Oncogene 2003; 22: 6220-6230. (Pubitemid 37281652)
22. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Formelli F et al. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993; 53: 6036-6041.
23. Ghiotto F, Fais F, Tenca C, Tomati V, Morabito F, Casciaro S et al. Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic. Cancer Biol Ther 2009; 8: 263-271.
24. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
25. Marachelian AKM, Hwang K, Villablanca JG, Groshen S, Matthay KK et al. Phase 1 study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial. J Clin Oncol 2009; 27 abs 10009.
26. Kummar S, Gutierrez ME, Maurer BJ, Reynolds CP, Kang M, Singh H et al. Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas. Anticancer Res 2011; 31: 961-966.
27. Mohrbacher A GM, Murgo AJ, Kummar S, Reynolds CP, Maurer BJ et al. Phase I trial of fenretinide (4-HPR) intravenous emulsion for hematologic malignancies. J Clin Oncol 2007; 25 (abs): 13007.
28. Allen JC, Talab F, Zuzel M, Lin K, Slupsky Jr. c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells. Blood 117: 2414-2422.
29. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008; 111: 4681-4689.
30. Sitailo LA, Tibudan SS, Denning MF. The protein kinase C delta catalytic fragment targets Mcl-1 for degradation to trigger apoptosis. J Biol Chem 2006; 281: 29703-29710. (Pubitemid 44536979)
31. Ruvolo VR, Karanjeet KB, Schuster TF, Brown R, Deng Y, Hinchcliffe E et al. Role for PKC delta in Fenretinide-Mediated Apoptosis in Lymphoid Leukemia Cells. J Signal Transduct 2010; 2010 584657.
32. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98: 13681-13686. (Pubitemid 33115958)
33. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365. (Pubitemid 43668734)
34. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. (Pubitemid 40825512)
35. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399. (Pubitemid 44711953)
36. Morel C, Carlson SM, White FM, Davis RJ. Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol Cell Biol 2009; 29: 3845-3852.
37. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 2007; 104: 6217-6222. (Pubitemid 47186075)
38. Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL et al. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 2007; 26: 1166-1177.
39. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7: 281-294. (Pubitemid 46480971)
40. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 2002; 100: 3741-3748. (Pubitemid 35303946)
41. Ringshausen I, Oelsner M, Weick K, Bogner C, Peschel C, Decker T. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia 2006; 20: 514-520. (Pubitemid 43291752)
42. Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, Raynaud SD et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene 2009; 28: 3261-3273.
43. O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ. N(4-hydroxyphenyl) retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 2002; 16: 902-910. (Pubitemid 34537564)
44. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003; 9: 2032-2039. (Pubitemid 36687622)
45. Villablanca JG, London WB, Naranjo A, McGrady P, Ames MM, Reid JM et al. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res 17: 6858-6866.
46. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006; 24: 3423-3430. (Pubitemid 46638899)
47. Reynolds CP, Frgala FT, Tsao-Wei DD, Groshen S, Morgan R, McNamara M et al. High plasma levels of fenretinide (4-HPR) were associated with improved outcome in a phase II study of recurrent ovarian cancer: A study by the California Cancer Consortium. J Clin Oncol 2007; 25(18Sabs): 5555.
48. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112-121. (Pubitemid 46048458)
49. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
50. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-4413.
51. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
52. Schoenwaelder SM, Jarman KE, Gardiner E, Hua M, Qiao J, White MJ et al. Bcl-xL inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118: 1663-1674.